Literature DB >> 3516261

Combined prophylactic suppression of graft-versus-host and host-versus-graft reactions following treatment of prospective bone marrow recipients with rat IgG 2b anti-mouse T cell antibodies.

S Thierfelder, U Kummer, G Hoffmann-Fezer, R Schuh.   

Abstract

A new approach to avoid typical complications from bone marrow transplantation into MHC different mice was studied. Rat monoclonal anti-Thy-1 antibodies of the IgG 2b isotype were identified, which inhibit T lymphocytes in vivo so that transplanted donor T cells as well as residual T cells of the conditioned marrow recipient were suppressed. A single injection of these antibodies after irradiation and before marrow transplantation did not only prevent graft-versus-host mortality but suppressed also host-versus-graft reactivity so that the radiation dose necessary for engraftment of donor cells differing in H-2, IA (both haplotypes) major histocompatibility antigens could be reduced to 6.0 Gy. In addition an anti-T leukemic cell effect from the injected monoclonal T cell antibodies was observed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3516261     DOI: 10.1007/bf00321086

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  14 in total

1.  Antilymphocytic antibodies and marrow transplantation. VI. Graft-versus-host tolerance in DLA-incompatible dogs after in vitro treatment of bone marrow with absorbed antithymocyte globulin.

Authors:  H J Kolb; I Rieder; H Rodt; B Netzel; H Grosse-Wilde; S Scholz; E Schäffer; H Kolb; S Thierfelder
Journal:  Transplantation       Date:  1979-04       Impact factor: 4.939

2.  GVHD suppression by incubation of bone marrow grafts with anti-T-cell globulin: effect in the canine model and application to clinical bone marrow transplantation.

Authors:  H Rodt; H J Kolb; B Netzel; I Rieder; G Janka; B Belohradsky; R J Haas; S Thierfelder
Journal:  Transplant Proc       Date:  1979-03       Impact factor: 1.066

3.  Prevention of acute graft-versus-host (GVH) mortality with spleen-absorbed antithymocyte globulin (ATG).

Authors:  J J Trentin; K P Judd
Journal:  Transplant Proc       Date:  1973-03       Impact factor: 1.066

4.  Suppression of acute secondary disease by heterologous anti-brain serum.

Authors:  H V Rodt; S Thierfelder; M Eulitz
Journal:  Blut       Date:  1972-12

5.  Bone marrow transplantation across major histocompatability barriers in mice. III. Treatment of donor grafts with monoclonal antibodies directed against Lyt determinants.

Authors:  D A Vallera; C C Soderling; J H Kersey
Journal:  J Immunol       Date:  1982-02       Impact factor: 5.422

6.  Bone marrow repopulation capacity after transplantation of lymphocyte-depleted allogeneic bone marrow using counterflow centrifugation.

Authors:  T de Witte; R Raymakers; A Plas; E Koekman; H Wessels; C Haanen
Journal:  Transplantation       Date:  1984-02       Impact factor: 4.939

Review 7.  Allogenic bone marrow transplantation: current status and future directions.

Authors:  R J O'Reilly
Journal:  Blood       Date:  1983-11       Impact factor: 22.113

8.  Anti-lymphocytic antibodies and marrow transplantation. 3. Effect of heterologous anti-brain antibodies on acute secondary disease in mice.

Authors:  H Rodt; S Thierfelder; M Eulitz
Journal:  Eur J Immunol       Date:  1974-01       Impact factor: 5.532

9.  Depletion of T lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukaemic marrow transplant recipients.

Authors:  H G Prentice; H A Blacklock; G Janossy; M J Gilmore; L Price-Jones; N Tidman; L K Trejdosiewicz; D B Skeggs; D Panjwani; S Ball
Journal:  Lancet       Date:  1984-03-03       Impact factor: 79.321

10.  Bone marrow transplantation across major histocompatibility barriers in mice. Effect of elimination of T cells from donor grafts by treatment with monoclonal Thy-1.2 plus complement or antibody alone.

Authors:  D A Vallera; C C Soderling; G J Carlson; J H Kersey
Journal:  Transplantation       Date:  1981-03       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.